AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
The independent analyst report highlights Vidac’s differentiated therapeutic platform, ongoing clinical advancements, and strong long-term potential in the oncology space.
Sphene Capital emphasized Vidac’s proprietary metabolic disruption strategy, which targets reversal of the Warburg effect—a hallmark of cancer cell metabolism. The company’s lead candidate, VDA-1102, is currently in Phase II clinical trials for cutaneous T-cell lymphoma (CTCL) and has demonstrated encouraging efficacy and safety results.
“We are pleased to see growing recognition from the investment community of Vidac Pharma’s scientific leadership and clinical momentum,” said Dr. Max Herzberg, Founder and Executive Chairman of Vidac Pharma. “This independent 'Buy' rating reflects the strength of our pipeline and the value creation potential we offer as we progress toward registration.”
The report also cited Vidac’s experienced leadership, robust intellectual property portfolio, and strategic positioning in addressing unmet medical needs in oncology—key factors supporting the company’s investment appeal.
Max Herzberg
Vidac pharma Holding Plc
+972 54-425-7381
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
